Japan approves Keytruda-Lenvima combo for renal cell carcinoma

The Keytruda plus Lenvima therapy is approved to treat metastatic renal cell carcinoma. Credit: 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.